278 results on '"Ganzinelli M"'
Search Results
2. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
3. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
4. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy
5. Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors:A Multicenter Cohort Study
6. PP01.01 PEOPLE (NTC03447678), a Phase II Trial to Test Biomarkers of Response to Pembrolizumab as First-Line Treatment in Advanced NSCLC Patients with PD-L1>50%
7. 25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils
8. EP.12A.05 Evaluation of the Role of VAF/cellularity as Proxy of Gene Aberration in EGFR Mutated Advanced NSCLC During Osimertinib.
9. 1071P Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients
10. 1056P KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC
11. 1079P Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations
12. EP08.01-006 Using Real World data to build effective predictive machine learining models for NSCLC patients treated with immune-based therapy
13. 1057P Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations
14. EP07.01-021 Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy
15. MA10.07 Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - STYLE Trial (NCT03449173)
16. P1.06B.11 Plasma MicroRNAs Profiling to Monitor Immunotherapy Response in Advanced NSCLC Patients
17. Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations
18. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations
19. KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC
20. Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients
21. SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma: 209P
22. P40.08 Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors
23. P50.06 First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate
24. P40.19 Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
25. 1236P Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
26. 1311P The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy
27. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
28. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy
29. Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts)
30. 2203P Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma
31. LBA98 Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial
32. 178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients
33. 1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib
34. 184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)
35. P33.01 Circulating Extracellular Vesicles as Biomarkers for Immune-Checkpoint Inhibitors in Advanced NSCLC
36. P2.11B.03 Circulating Hallmarks of Hyperprogression in NSCLC upon 1st Line PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy
37. Predicting the role of dna polymerase β alone or with kras mutations in advanced nsclc patients receiving platinum-based chemotherapy
38. 68P OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC
39. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents
40. 1312P Chemotherapy followed by immunotherapy compared to reverse sequence in NSCLC with PD-L1 low expression: PFS2 analysis
41. 1329P Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers in a real world experience
42. Characterization of patients with metastatic Non Small Cell Lung Cancer obtaining Long Term Benefit from Immunotherapy
43. The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
44. DEMo: A prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy
45. P1.01-135 Salvage Chemotherapy After Immunotherapy Failure in Non-Small-Cell Lung Cancer Patients
46. OA14.06 Hyperprogressive Disease in Advanced Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
47. P1.04-38 Efficacy and Safety of Immunotherapy in Elderly Patients with Non-Small Cell Lung Cancer
48. MA03.10 Prospective Evaluation of a Prognostic Clinico-Molecular Score (DEMo) to Predict Outcome of Advanced NSCLC Patients Treated with Immunotherapy
49. P2.09-05 Clinical and Biological Characterization of Lung Enteric Adenocarcinoma
50. Prognostic role of CD73 in metastatic non small cell lung cancer according to the presence of driver alterations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.